Clinical trials: Venous Thromboembolic Event
Venous Thromboembolism
A Trial to Learn How Well REGN9933 and REGN7508 Work for Preventing Blood Clots, and How Safe They Are, in Adults Who Have a Peripherally Inserted Central Catheter (PICC)
This study is researching 2 different experimental drugs called REGN9933 and REGN7508 (called "study drugs"). The study is focused on adults undergoing a placement of a catheter in the vein, also called a 'PICC line'.
- Trial name
- ROXI-CATH (NCT06299111)
- Testing
- REGN9933, REGN7508
- Where
- 23 sites in United States, Bulgaria and 4 more
- Volunteers
- 195 people
- Sponsor
- Regeneron Pharmaceuticals
Assisted Reproductive Techniques, Pregnancy
Incidence of Pulmonary and Venous Thromboembolism in IVF Pregnancies After Fresh and Frozen Embryo Transfer
In vitro fertilization (IVF) is associated with an increased risk of venous thromboembolism and in particular pulmonary embolism during the first trimester.
- Conditions
- Assisted Reproductive Techniques, Pregnancy, Pulmonary Embolism, Venous Thromboembolism
- Trial name
- NCT03660007
- Testing
- Fresh or frozen embryo transfer IVF
- Volunteers
- 902,891 people
- Sponsor
- Karolinska Institutet
Venous Thromboembolism, Pelvic Surgery
Venous Thrombo-embolic Complication prévention in Pelvic Surgery
Pelvic fracture surgery are very high thrombotic risk surgery with about 10% to 50% venous thrombo embolic complications and 0.5% to 10% of pulmonary embolism. The ST JOSEPH's Hospital have almost 60 cases per year .
- Trial name
- NCT03535428
- Testing
- VENOUS exploration
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Fondation Hôpital Saint-Joseph
Contraception, Female Contraception
Postmarketing Study of ORTHO EVRA (Norelgestromin and Ethinyl Estradiol Contraceptive Patch) in Relation to Venous Thromboembolism (Blood Clots), Stroke and Heart Attacks
The purpose of the study is to assess the occurrence of venous thromboembolism (blood clots), stroke, and heart attack in current users of ORTHO EVRA compared to current users of norgestimate-containing oral contraceptives with…
- Trial name
- NCT00331071
- Testing
- Monophasic or triphasic Oral contraceptive tablet, Ortho Evra transdermal patch containing 6 mg NGMN/0.75 mg EE
- Volunteers
- 334 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Thromboembolism
Efficacy and Safety of Dabigatran Compared to Warfarin for 6 Month Treatment of Acute Symptomatic Venous Thromboembolism
The purpose of this trial is to determine the comparative safety and efficacy of dabigatran etexilate 150 mg bid administered orally and warfarin as needed (pro re nata - prn) to maintain an International Normalised Ratio (INR)…
- Trial name
- RE-COVER I (NCT00291330)
- Testing
- dabigatran etexilate 150 mg, warfarin (INR 2-3)
- Where
- 250 sites in United States, Argentina and 27 more
- Volunteers
- 2,564 people
- Sponsor
- Boehringer Ingelheim
Venous Thromboembolism, Deep Venous Thrombosis
Enoxaparin Metabolism in Reconstructive Surgery Patients
Venous thromboembolism (VTE) is a leading cause of death among hospitalized patients, and is an important patient safety issue in plastic surgery.
- Conditions
- Venous Thromboembolism, Deep Venous Thrombosis, Pulmonary Embolus, Reconstructive Surgery
- Trial name
- NCT02411292
- Testing
- Enoxaparin
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- University of Utah
Deep Vein Thrombosis, Pulmonary Embolism
D-dimer to Select Patients With First Unprovoked Venous Thromboembolism Who Can Have Anticoagulants Stopped at 3 Months
The purpose of this study is to determine if the risk of recurrent venous thromboembolism (VTE) after stopping therapy is low and acceptable in patients with a first unprovoked proximal deep vein thrombosis (DVT) or pulmonary…
- Trial name
- DODS (NCT00720915)
- Testing
- Discontinue anticoagulant therapy (Negative d-dimer), Continue on anticoagulant therapy (positive d-dimer)
- Where
- 13 sites in United States, Canada and 2 more
- Volunteers
- 410 people
- Sponsor
- McMaster University
Contraception
European Active Surveillance Study (EURAS)
EURAS is a multi-national, controlled, prospective, post-marketing, non-intervention cohort study of new users of drospirenone/ethinylestradiol (DRSP/EE), levonorgestrel/ethinylestradiol (LNG/EE) and other oral contraceptives…
- Trial name
- NCT00302848
- Testing
- Drospirenone, Levonorgestrel, Other progestin containing oral contraceptive
- Where
- Germany
- Volunteers
- 59,510 people, healthy volunteers welcome
- Sponsor
- Center for Epidemiology and Health Research, Germany
Venous Thromboembolic Disease
The Role of FDG-PET/CT Imaging in the Management of Patients With Thromboembolic Disorders (The PETVET Study)
This pilot study aims at validating 18F-flourodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) in the detection and characterization of venous thromboembolism (VTE) in the entire human body, especially…
- Trial name
- PETVET (NCT01466426)
- Where
- 3 sites in Denmark
- Volunteers
- 40 people
- Sponsor
- Odense University Hospital
Venous Thromboembolism
Platelet FcGammaRIIa and Risk of Venous Thromboembolism in Cancer
Thrombosis is common and contributes significantly to morbidity and mortality in patients with cancer. At least 20% of patients with cancer develop venous thromboembolism (VTE) and another 5% will experience acute arterial…
- Trial name
- NCT05240508
- Where
- United States
- Volunteers
- 600 people
- Sponsor
- University of Vermont
Venous Thromboembolism
Effect of Intravenous Continuous Infusion Heparin on Rates of Venous Thromboembolism in High-Risk, Critically Ill Patients
The primary purpose of this study is to demonstrate that a continuous infusion of intravenous (IV) heparin (UFH) for Venous thromboembolism (VTE) prophylaxis will restore prophylactic levels of heparin in high-risk critically ill…
- Trial name
- NCT02707263
- Testing
- intravenous continuous infusion of heparin (IV UFH), Subcutaneous Heparin
- Where
- United States
- Sponsor
- NYU Langone Health
Deep Vein Thrombosis, Pulmonary Embolism and Thrombosis
Apixaban in Thrombocytopenia
This study is being done to determine the feasibility and safety of using a novel dose adjusted apixaban for the management of participants with cancer-associated venous thromboembolism (blood clot) or and thrombocytopenia (low…
- Conditions
- Deep Vein Thrombosis, Pulmonary Embolism and Thrombosis, Thrombocytopenia, Recurrent Venous Thromboembolism
- Trial name
- NCT06886516
- Testing
- Apixaban
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Rushad Patell
Thromboembolic Venous Disease
New Genetic Mutations in Thromboembolic Venous Disease Idiopathic. Study "FIT GENETIQUE".
Identify new genetic mutations predisposing to an increased risk of VTE by locating and / or identifying genes involved in subjects at high risk for thrombotic and in whom screening for detectable hereditary thrombophilia was…
- Trial name
- Fit-Génétique (NCT02841085)
- Testing
- Genetic sample
- Where
- France
- Volunteers
- 613 people
- Sponsor
- University Hospital, Brest
Heavy Menstrual Bleeding
Prospective Comparison of Incidence of Heavy Menstrual Bleeding in Women Treated With Direct Oral Anticoagulants
Prospective comparison of the incidence of heavy menstrual bleeding (HMB) in women of reproductive age treated with direct oral anticoagulants (DOACs)
- Trial name
- NCT04477837
- Testing
- Apixaban 5 MG, Rivaroxaban 20 MG, Edoxaban 60 MG
- Where
- Germany
- Volunteers
- 84 people
- Sponsor
- Cardioangiologisches Centrum Bethanien
Venous Thromboembolism (VTE)
Diagnostic and Prognostic Prediction Models for Chinese Patients With Venous Thromboembolism
The objective of this proposal is to develop and validate diagnostic and prognostic (including short-term and long-term prognoses) prediction models for patients with venous thromboembolism (VTE) in China.
- Trial name
- NCT03802929
- Where
- China
- Volunteers
- 4,000 people
- Sponsor
- Ya-Wei Xu
Cerebral Venous Sinus Thrombosis, Stroke
Danang Cerebral Venous Thrombosis Registry
Cerebral venous thrombosis (CVT) is an uncommon but potentially life-threatening type of stroke, predominantly affecting young adults and women.
- Conditions
- Cerebral Venous Sinus Thrombosis, Stroke, Cerebral Venous Thrombosis
- Trial name
- DANANG-CVT (NCT07890675)
- Testing
- Standard Anticoagulant Therapy
- Where
- Vietnam
- Volunteers
- 110 people
- Sponsor
- Da Nang Hospital
Atrial Fibrillation (AF)
Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable
This study is researching 2 different experimental drugs called REGN7508 and REGN9933 (called "study drugs"). The study is focused on people who have atrial fibrillation, which means that the heart beats too fast and unevenly.
- Trial name
- ROXI-INCLINE (NCT07430956)
- Testing
- REGN7508, REGN9933
- Where
- 44 sites in United States, Canada
- Volunteers
- 2,628 people
- Sponsor
- Regeneron Pharmaceuticals
Venous Thromboembolism
Special Drug Use Investigation of Xarelto for Venous Thromboembolism (VTE)
The objective of this investigation is to assess safety and effectiveness of Xarelto under practice routine use in VTE secondary prevention after acute DVT, focusing on hemorrhagic-related AEs, recurrent venous thromboembolism…
- Trial name
- JPMS-XAR-VTE (NCT02558465)
- Testing
- Rivaroxaban (Xarelto, BAY59-7939)
- Where
- Japan
- Volunteers
- 2,540 people
- Sponsor
- Bayer
Venous Thromboembolism
Computerized Registry of Patients With Venous Thromboembolism (RIETE)
The Computerized Registry of Patients with Venous Thromboembolism (RIETE) is a multidisciplinary Project initiated in march 2001 and consisting in obtaining an extensive data registry of consecutive patients with venous…
- Trial name
- RIETE (NCT02832245)
- Where
- 305 sites in United States, Argentina and 27 more
- Volunteers
- 120,000 people
- Sponsor
- Manuel Monreal
Thrombosis, Venous
Total Hip Replacement Study Of GSK576428 (Fondaparinux Sodium)
This study is requested by PMDA to confirm the optimal dose for THR (total hip replacement).
- Trial name
- NCT00320398
- Testing
- Fondaparinux
- Volunteers
- 114 people
- Sponsor
- GlaxoSmithKline